Scientists become dealmakers as drugmakers seek acquisition targets

Scientists are adding dealmaker to their repertoire of skills as drugmakers increasingly compete for experimental compounds developed outside their own companies to fill their pipelines. These scientists travel the globe to build relationships, weigh the merits of promising compounds and startups, and negotiate licensing or acquisition deals.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Briefs: